buy rating $3

$Azitra (AZTR.US)$ Azitra Inc. has received a 'Buy' rating, bolstered by significant progress in its ATR-12 and ATR-04 programs. ATR-12, a genetically modified strain of Staphylococcus epidermidis, is being developed to treat Netherton syndrome, a severe and chronic skin disorder. The company has initiated a Phase 1b clinical trial for ATR-12, marking a crucial step in its development. Additionally, the FDA has granted Fast Track designation to ATR-04, another genetically modified strain of S. epidermidis, intended to address papulopustular rash associated with EGFR inhibitor cancer therapies. These advancements underscore Azitra's commitment to developing innovative dermatological treatments. ​​​